WGU D116 Unit 2 Questions with
complete solution 2026
A. Monitor plasma drug levels
1. A patient receives a drug that has a
narrow therapeutic range. What is the A drug with a narrow therapeutic
nurse admin-istering this medication
expected to do? range is more diflcult to administer
safely be-cause the ditterence
A. Monitor plasma drug levels. between the mini-mum ettective
B. Administer the drug at intervals concentration (MEC ) and the toxic
longer than the drug half-life. concentration is small. Patients taking
these medications must have their
C. Teach the patient that maximum drug plasma drug levels monitored
ef-fects will occur within a short period.
closely to ensure that they are
D. Administer this medication getting an ettective dose that is not
intravenously toxic.
2. A patient is receiving intravenous
gentam-icin. A serum drug test reveals
toxic levels. The dosing is correct, and D. The patient is taking another
this medication has been tolerated by
this patient in the past. medica-tion that binds to serum
albumin.
What is a probable cause of the test
result? Correct! Gentamicin binds to
A. The drug was not completely dissolved albumin, but only weakly. In the
in the IV solution. presence of an-other drug that
binds to albumin, gen-tamicin can
B. A loading dose was not given. rise to toxic levels in blood
C.The medication is being given at a serum.
frequen-cy that is longer than its half-life.
D. The patient is taking another
medication that binds to serum
albumin.
3.
, WGU D116 Unit 2
What are the components of pharmacokinet- Absorption, distribution, metabolism,
ex-
ics? cretion
4. Does the volume of distribution increase DECREASES
or decrease as the concentration of a
drug in the blood plasma increases?
5. A patient reports becoming "immune"
to a medication because it no longer C. Desensitization of receptor sites by
works to alleviate symptoms.
continual exposure to the drug
The provider recognizes that this
decreased effectiveness is likely caused
by what? Continual exposure to an agonist
would cause the cell to become less
A. synthesis of more receptor sites in responsive or desensitized
re-sponse to the medication
B. decreased selectivity of receptor sites,
re-sulting in a variety of effects
C. desensitization of receptor sites by
contin-ual exposure to the drug
D. antagonists produced by the body
that compete with the drug for
receptor sites
6. What occurs when a drug binds to a receptor A. It increases or decreases the
activity of
in the body? that receptor
A. It increases or decreases the activity Correct! When a drug binds to a
of that receptor.
recep-tor, it mimics or blocks the
B. It alters the receptor to become actions of the usual endogenous
non-responsive to its usual endogenous regulatory molecules, either
mole-cules. increasing or decreasing the rate
, WGU D116 Unit 2
of the physiologic activity normally
C. It prevents the action of the receptor
by altering its response to chemical con-trolled by that receptor.
mediators.
D. It gives the receptor a new function.
7. Which pharmacodynamic principle is A. Therapeutic index
most correlated with drug toxicity?
A. Therapeutic index Which is calculated by dividing the
me-dian toxic dose by the median
B. Intrinsic activity eflcacious dose
C. Competitive antagonists
D. Efficacy
8. A patient who is taking morphine for
pain asks the nurse how a pain
medication can also cause
constipation. C. It is selective to receptors that
What is the nurse's response? regulate more than one body
process
A. It binds to different types of receptors
in the body. Correct! Morphine is a medication that
is selective to receptor types that
B. It can cause constipation in toxic
doses. regulate more than one process.
C. It is selective to receptors that
regulate more than one body process.
D. It causes only one type of response,
and the constipation is coincidental.
9.
complete solution 2026
A. Monitor plasma drug levels
1. A patient receives a drug that has a
narrow therapeutic range. What is the A drug with a narrow therapeutic
nurse admin-istering this medication
expected to do? range is more diflcult to administer
safely be-cause the ditterence
A. Monitor plasma drug levels. between the mini-mum ettective
B. Administer the drug at intervals concentration (MEC ) and the toxic
longer than the drug half-life. concentration is small. Patients taking
these medications must have their
C. Teach the patient that maximum drug plasma drug levels monitored
ef-fects will occur within a short period.
closely to ensure that they are
D. Administer this medication getting an ettective dose that is not
intravenously toxic.
2. A patient is receiving intravenous
gentam-icin. A serum drug test reveals
toxic levels. The dosing is correct, and D. The patient is taking another
this medication has been tolerated by
this patient in the past. medica-tion that binds to serum
albumin.
What is a probable cause of the test
result? Correct! Gentamicin binds to
A. The drug was not completely dissolved albumin, but only weakly. In the
in the IV solution. presence of an-other drug that
binds to albumin, gen-tamicin can
B. A loading dose was not given. rise to toxic levels in blood
C.The medication is being given at a serum.
frequen-cy that is longer than its half-life.
D. The patient is taking another
medication that binds to serum
albumin.
3.
, WGU D116 Unit 2
What are the components of pharmacokinet- Absorption, distribution, metabolism,
ex-
ics? cretion
4. Does the volume of distribution increase DECREASES
or decrease as the concentration of a
drug in the blood plasma increases?
5. A patient reports becoming "immune"
to a medication because it no longer C. Desensitization of receptor sites by
works to alleviate symptoms.
continual exposure to the drug
The provider recognizes that this
decreased effectiveness is likely caused
by what? Continual exposure to an agonist
would cause the cell to become less
A. synthesis of more receptor sites in responsive or desensitized
re-sponse to the medication
B. decreased selectivity of receptor sites,
re-sulting in a variety of effects
C. desensitization of receptor sites by
contin-ual exposure to the drug
D. antagonists produced by the body
that compete with the drug for
receptor sites
6. What occurs when a drug binds to a receptor A. It increases or decreases the
activity of
in the body? that receptor
A. It increases or decreases the activity Correct! When a drug binds to a
of that receptor.
recep-tor, it mimics or blocks the
B. It alters the receptor to become actions of the usual endogenous
non-responsive to its usual endogenous regulatory molecules, either
mole-cules. increasing or decreasing the rate
, WGU D116 Unit 2
of the physiologic activity normally
C. It prevents the action of the receptor
by altering its response to chemical con-trolled by that receptor.
mediators.
D. It gives the receptor a new function.
7. Which pharmacodynamic principle is A. Therapeutic index
most correlated with drug toxicity?
A. Therapeutic index Which is calculated by dividing the
me-dian toxic dose by the median
B. Intrinsic activity eflcacious dose
C. Competitive antagonists
D. Efficacy
8. A patient who is taking morphine for
pain asks the nurse how a pain
medication can also cause
constipation. C. It is selective to receptors that
What is the nurse's response? regulate more than one body
process
A. It binds to different types of receptors
in the body. Correct! Morphine is a medication that
is selective to receptor types that
B. It can cause constipation in toxic
doses. regulate more than one process.
C. It is selective to receptors that
regulate more than one body process.
D. It causes only one type of response,
and the constipation is coincidental.
9.
